drugset / Trial / NCT03442621

Relacorilant Food Effect Study in Healthy Subjects

NCT03442621

Phase 1 Completed 30 enrolled Corcept Therapeutics
RandomizedCrossoverOpen-labelOther

Summary

This is an open-label, randomized, single-dose, 3-period crossover, Williams' design, food-interaction (fasted and fed arms) study conducted in healthy subjects.

Timeline

Start
2018-01-16
Primary completion
2018-02-28
Completion
2018-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Relacorilant Small molecule 350 mg Oral

Indications

No indication recorded.